Psychedelics and Approval

Michael discusses the promising path of psychedelics towards FDA approval, highlighting ongoing phase two and upcoming phase three trials for psilocybin in treating depression and anxiety. He notes the lack of involvement from big pharma due to expired patents on substances like LSD and psilocybin, emphasizing the urgency of addressing the growing depression crisis in the general population.